Brief: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease

Palatin Technologies

28/02/2024 12:40

Feb 28 (Reuters) - Palatin Technologies Inc  PTN.A :
    * PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE
3
CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE (DED)
    * PALATIN TECHNOLOGIES INC - MULTIPLE SECONDARY SYMPTOM
ENDPOINTS
MET, STATISTICAL SIGNIFICANCE (P<0.025)
    * PALATIN TECHNOLOGIES INC - ON AN INTENT-TO-TREAT ANALYSIS,
CO-PRIMARY SYMPTOM ENDPOINT MET, STATISTICAL SIGNIFICANCE
(P<0.025)
    * PALATIN TECHNOLOGIES INC - ON AN INTENT-TO-TREAT ANALYSIS,
CO-PRIMARY SIGN ENDPOINT AND SECONDARY SIGN ENDPOINTS NOT MET
    * PALATIN TECHNOLOGIES INC - ON AN INTENT-TO-TREAT ANALYSIS,
CO-PRIMARY SIGN ENDPOINT AND SECONDARY SIGN ENDPOINTS NOT MET

Source text for Eikon:  ID:nPnrJkw3a 
Further company coverage:  PTN.A 

 ((Reuters.Briefs@thomsonreuters.com;))